Pairnomix today announced that CEO Matthew Fox will present at KCNQ2 Cure’s 2016 Family and Professional Summit, October 7-9, 2016 in Silver Spring, MD. This three-day event is designed to unite all groups committed to improving the lives of those with KCNQ2 Epilepsy.
About the Presentation
Fox will deliver a talk entitled Pairnomix Introduction: Deciphering Genomes, Delivering Knowledge, on Sunday, October 9 at 10:45 am at the Sheraton Hotel.
“We look forward to engaging with families and healthcare professionals impacted by KCNQ2 epileptic encephalopathy,” said Matthew Fox, CEO, Pairnomix. “We’ve been working closely with the KCNQ2 Cure Alliance to bring our highly personalized genetic evaluations to individuals in this community and are proud of the research advancements we have made to date.”
Pairnomix’s KCNQ2 Research
Pairnomix offers unique characterization and drug screening services that provide physicians with data on a patient’s rare genetic mutation and on potential treatment options that are currently available.
Last year, Pairnomix and the KCNQ2 Cure Alliance entered into a collaboration to further explore genetic mutations in KCNQ2 epileptic encephalopathy with the goal of identifying more effective and more accurately targeted therapies. It is estimated that 200 people worldwide have been diagnosed with KCNQ2 epileptic encephalopathy. However, many more are believed to be affected by this rare genetic mutation, but have not yet been diagnosed due to its relatively recent discovery and availability of testing.
Upcoming Scientific Meetings
In addition to the KCNQ2 Cure’s 2016 Family and Professional Summit, Pairnomix will have a presence at a number of upcoming medical meetings, including: the Child Neurology Society Annual Meeting, October 26-29, 2016 in Vancouver, BC; and a presentation of data at the American Epilepsy Society Annual Meeting, December 2-6, 2016 in Houston, TX.
Pairnomix™, a genetic research company, is committed to helping people living with rare diseases understand the genetic cause of their condition and explore potential treatment options that are available today. Pairnomix’ initial focus is on advancing personalized research for people living with epilepsy and other disorders of the Central Nervous System. To learn more, please visit www.pairnomix.com.
MAPLE GROVE, Minn., October 7, 2016 /PRNewswire/